Literature DB >> 16483750

Autoantibody biomarker opens a new gateway for cancer diagnosis.

M Nesterova1, N Johnson, C Cheadle, Y S Cho-Chung.   

Abstract

The list of cancer markers of current interest has grown considerably, but none of the markers used in clinical work is a true tumor marker. These cancer biomarkers are based on the determination of tumor antigens. Here, we report a single method of autoantibody enzyme immunoassay (EIA) screens for a spectrum of serum tumor markers. A comparison of the autoantibody-based EIA to conventional antigen EIA kits, using receiver operating characteristic (ROC) plots, showed that the autoantibody EIA can significantly enhance the sensitivity and specificity of tumor markers. The detection of serum autoantibodies for a spectrum of serum tumor markers, as demonstrated here, suggests that most, if not all, serum cancer biomarkers produce autoantibodies. A unique autoantibody biomarker screening method, as presented here, might therefore facilitate achieving the accurate and early diagnosis of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483750     DOI: 10.1016/j.bbadis.2005.12.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme.

Authors:  Matthew J Webber; Christina J Newcomb; Ronit Bitton; Samuel I Stupp
Journal:  Soft Matter       Date:  2011-10-21       Impact factor: 3.679

2.  Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Authors:  Aykan A Karabudak; Julie Hafner; Vivekananda Shetty; Songming Chen; Angeles Alvarez Secord; Michael A Morse; Ramila Philip
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-03       Impact factor: 4.553

3.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

Review 4.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

5.  Preferential recognition of auto-antibodies against 4-hydroxynonenal modified DNA in the cancer patients.

Authors:  Mohammad Faisal; Uzma Shahab; Abdulrahman A Alatar; Saheem Ahmad
Journal:  J Clin Lab Anal       Date:  2017-01-20       Impact factor: 2.352

6.  Autoantibodies to mesothelin in infertility.

Authors:  Judith L Luborsky; Yi Yu; Seby L Edassery; Jade Jaffar; Yuan Yee Yip; Pu Liu; Karl Eric Hellstrom; Ingegerd Hellstrom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-16       Impact factor: 4.254

7.  Technical validation of an autoantibody test for lung cancer.

Authors:  A Murray; C J Chapman; G Healey; L J Peek; G Parsons; D Baldwin; A Barnes; H F Sewell; H A Fritsche; J F R Robertson
Journal:  Ann Oncol       Date:  2010-02-02       Impact factor: 32.976

Review 8.  Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Authors:  Elizabeth R Rayburn; Ruiwen Zhang
Journal:  Drug Discov Today       Date:  2008-05-03       Impact factor: 7.851

9.  Anti-HE4 antibodies in infertile women and women with ovarian cancer.

Authors:  Ingegerd Hellstrom; Elizabeth Swisher; Karl Erik Hellstrom; Yuen Yee Yip; Kathy Agnew; Judith L Luborsky
Journal:  Gynecol Oncol       Date:  2013-05-28       Impact factor: 5.482

10.  Serum tumor markers in pediatric osteosarcoma: a summary review.

Authors:  Yulia A Savitskaya; Genaro Rico-Martínez; Luis Miguel Linares-González; Ernesto Andrés Delgado-Cedillo; René Téllez-Gastelum; Alfonso Benito Alfaro-Rodríguez; Antonio Redón-Tavera; José Clemente Ibarra-Ponce de León
Journal:  Clin Sarcoma Res       Date:  2012-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.